OBJECTIVE: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of patients with systemic sclerosis (SSc) and has a major impact on health-related quality of life (HRQOL). We developed an HRQOL instrument for persons with SSc. METHODS: The Scleroderma Gastrointestinal Tract 1.0 (SSC-GIT 1.0) survey was developed after an extensive literature search, solicitation and consideration of experts' opinions, and 2 focus groups of 16 subjects with SSc and GIT involvement. A 75-item, self-reported measure assessing bowel involvement, emotional well-being, and social functioning was administered to subjects with SSc and GIT involvement. Also, subjects completed the Short Form 36 and rated the severity of their GIT symptoms (very mild to very severe), and items were transformed linearly to a scale with a possible range of 0 (worse health) to 100 (better health). Evaluation of psychometric properties included internal consistency reliability, test-retest reliability (1.3-week median time interval), multitrait scaling analysis, and exploratory factor analysis. RESULTS: Study participants (n = 88) were primarily female (95.5%), white (79.3%), and had a mean age of 52.4 years. Self-rated severity of GIT involvement ranged from very mild or mild (36.0%) to moderate (44.0%) to severe or very severe (20.0%). Of 75 items, 23 had low item-total correlations (</=0.39) and were excluded, leaving a 52-item instrument. Analyses supported 6 multi-item HRQOL scales: reflux/indigestion, diarrhea, constipation, pain, emotional well-being, and social functioning. Test-retest reliability estimates ranged 0.69-0.90 and Cronbach's alpha ranged 0.69-0.93. Participants who rated their GIT disease as mild had the highest scores (better health) on all 6 scales; participants who rated their GIT as severe had the lowest scores (poor health). CONCLUSION: The results support the reliability and validity of the SSC-GIT 1.0 as a measure of SSc GIT involvement. Further research is needed to examine the ability to detect change over time and define minimally important differences.
OBJECTIVE: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of patients with systemic sclerosis (SSc) and has a major impact on health-related quality of life (HRQOL). We developed an HRQOL instrument for persons with SSc. METHODS: The Scleroderma Gastrointestinal Tract 1.0 (SSC-GIT 1.0) survey was developed after an extensive literature search, solicitation and consideration of experts' opinions, and 2 focus groups of 16 subjects with SSc and GIT involvement. A 75-item, self-reported measure assessing bowel involvement, emotional well-being, and social functioning was administered to subjects with SSc and GIT involvement. Also, subjects completed the Short Form 36 and rated the severity of their GIT symptoms (very mild to very severe), and items were transformed linearly to a scale with a possible range of 0 (worse health) to 100 (better health). Evaluation of psychometric properties included internal consistency reliability, test-retest reliability (1.3-week median time interval), multitrait scaling analysis, and exploratory factor analysis. RESULTS: Study participants (n = 88) were primarily female (95.5%), white (79.3%), and had a mean age of 52.4 years. Self-rated severity of GIT involvement ranged from very mild or mild (36.0%) to moderate (44.0%) to severe or very severe (20.0%). Of 75 items, 23 had low item-total correlations (</=0.39) and were excluded, leaving a 52-item instrument. Analyses supported 6 multi-item HRQOL scales: reflux/indigestion, diarrhea, constipation, pain, emotional well-being, and social functioning. Test-retest reliability estimates ranged 0.69-0.90 and Cronbach's alpha ranged 0.69-0.93. Participants who rated their GIT disease as mild had the highest scores (better health) on all 6 scales; participants who rated their GIT as severe had the lowest scores (poor health). CONCLUSION: The results support the reliability and validity of the SSC-GIT 1.0 as a measure of SSc GIT involvement. Further research is needed to examine the ability to detect change over time and define minimally important differences.
Authors: D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst Journal: Ann Rheum Dis Date: 2007-09-24 Impact factor: 19.103
Authors: Puja Khanna; Nikhil Agarwal; Dinesh Khanna; Ron D Hays; Lin Chang; Roger Bolus; Gil Melmed; Cynthia B Whitman; Robert M Kaplan; Rikke Ogawa; Bradley Snyder; Brennan Mr Spiegel Journal: Am J Gastroenterol Date: 2013-12-17 Impact factor: 10.864
Authors: Luiza F Rocha; Roberta G Marangoni; Percival D Sampaio-Barros; Mauricio Levy-Neto; Natalino H Yoshinari; Eloisa Bonfa; Virginia Steen; Sergio C Kowalski Journal: Clin Rheumatol Date: 2013-08-22 Impact factor: 2.980
Authors: T A McNearney; H S Sallam; S E Hunnicutt; D Doshi; D E Wollaston; M D Mayes; J D Z Chen Journal: Neurogastroenterol Motil Date: 2009-06-30 Impact factor: 3.598
Authors: Brennan M R Spiegel; Dinesh Khanna; Roger Bolus; Nikhil Agarwal; Puja Khanna; Lin Chang Journal: Am J Gastroenterol Date: 2011-03 Impact factor: 10.864
Authors: Dinesh Khanna; Daniel E Furst; Paul Maranian; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Terri Getzug; Ron D Hays Journal: J Rheumatol Date: 2011-07-01 Impact factor: 4.666
Authors: Dinesh Khanna; Ron D Hays; Paul Maranian; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Terri Getzug; Nihal Fathi; Amber Bechtel; Daniel E Furst Journal: Arthritis Rheum Date: 2009-09-15